Improved prognosis of septic shock in patients with cirrhosis: A multicenter study

Critical Care Medicine

Volumn 42, Issue 7, 2014, Pages 1666-1675

  Galbois, Arnaud ^a,b,c   Aegerter, Philippe ^d,e   Martel Samb, Patricia ^d,e   Housset, Chantal ^a,b,c   Thabut, Dominique ^b,c,f   Offenstadt, Georges ^a,b,g   Ait Oufella, Hafid ^a,b   Maury, Eric ^a,b,g   Guidet, Bertrand ^a,b,g  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g INSERM   (France)

Author keywords

critical care; humans; liver cirrhosis; prognosis; septic shock

Indexed keywords

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PERITONITIS; BLOOD CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ESCHERICHIA COLI; FEMALE; FUNGUS; HUMAN; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYCOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEPTIC SHOCK; SIMPLIFIED ACUTE PHYSIOLOGY SCORE;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 84902544527     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000321     Document Type: Article

References (52)

1. Arvaniti V, D'Amico G, Fede G, et al: Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139:1246-1256, 1256.e1-1256.e5
2. Foreman MG, Mannino DM, Moss M: Cirrhosis as a risk factor for sepsis and death: Analysis of the National Hospital Discharge Survey. Chest 2003; 124:1016-1020
3. Gustot T, Durand F, Lebrec D, et al: Severe sepsis in cirrhosis. Hepatology 2009; 50:2022-2033
4. Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256
5. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
6. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
7. Annane D, Aegerter P, Jars-Guincestre MC, et al: Current epidemiology of septic shock: The CUB-Rea Network. Am J Respir Crit Care Med 2003; 168:165-172
8. Brun-Buisson C, Meshaka P, Pinton P, et al; EPISEPSIS Study Group: EPISEPSIS: A reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30:580-588
9. Dombrovskiy VY, Martin AA, Sunderram J, et al: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007; 35:1244-1250
10. Kumar G, Kumar N, Taneja A, et al: Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011; 140:1223-1231
11. Banta JE, Joshi KP, Beeson L, et al: Patient and hospital characteristics associated with inpatient severe sepsis mortality in California, 2005-2010. Crit Care Med 2012; 40:2960-2966
12. Guidet B, Martinet O, Boulain T, et al: Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012; 16:R94
13. Perner A, Haase N, Guttormsen AB, et al; 6S Trial Group; Scandinavian Critical Care Trials Group: Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367:124-134
14. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
15. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
16. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301-1308
17. Schiffl H, Lang SM, Fischer R: Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346:305-310
18. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596
19. Kumar A, Ellis P, Arabi Y, et al; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group: Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237-1248
20. Castellanos-Ortega A, Suberviola B, García-Astudillo LA, et al: Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year follow-up quasi-experimental study. Crit Care Med 2010; 38:1036-1043
21. Shiramizo SC, Marra AR, Durão MS, et al: Decreasing mortality in severe sepsis and septic shock patients by implementing a sepsis bundle in a hospital setting. PLoS One 2011; 6:e26790
22. Zuber B, Tran TC, Aegerter P, et al; CUB-Réa Network: Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med 2012; 40:55-62
23. Dres M, Tran TC, Aegerter P, et al: Influence of ICU case-volume on the management and hospital outcomes of acute exacerbations of chronic obstructive pulmonary disease. Crit Care Med 2013; 41:1884-1892
24. Moreau R, Hadengue A, Soupison T, et al: Septic shock in patients with cirrhosis: Hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med 1992; 20:746-750
25. Plessier A, Denninger MH, Consigny Y, et al: Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int 2003; 23:440-448
26. Galbois A, Trompette ML, Das V, et al: Improvement in the prognosis of cirrhotic patients admitted to an intensive care unit, a retrospective study. Eur J Gastroenterol Hepatol 2012; 24:897-904
27. Sauneuf B, Champigneulle B, Soummer A, et al: Increased survival of cirrhotic patients with septic shock. Crit Care 2013; 17:R78
28. O'Brien AJ, Welch CA, Singer M, et al: Prevalence and outcome of cirrhosis patients admitted to UK intensive care: A comparison against dialysis-dependent chronic renal failure patients. Intensive Care Med 2012; 38:991-1000
29. Das V, Boelle PY, Galbois A, et al: Cirrhotic patients in the medical intensive care unit: Early prognosis and long-term survival. Crit Care Med 2010; 38:2108-2116
30. Levesque E, Hoti E, Azoulay D, et al: Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol 2012; 56:95-102
31. Galbois A, Das V, Carbonell N, et al: Prognostic scores for cirrhotic patients admitted to an intensive care unit: Which consequences for liver transplantation? Clin Res Hepatol Gastroenterol 2013; 37:455-466
32. Ginès P, Fernández J, Durand F, et al: Management of critically-ill cirrhotic patients. J Hepatol 2012; 56(Suppl 1):S13-S24
33. Fernández J, Gustot T: Management of bacterial infections in cirrhosis. J Hepatol 2012; 56(Suppl 1):S1-12
34. Aegerter P, Auvert B, Buonamico G, et al: [Organization and quality control of a clinical database on intensive care medicine in central and suburban Paris]. Rev Epidemiol Sante Publique 1998; 46:226-237
35. Black N, Payne M: Directory of clinical databases: Improving and promoting their use. Qual Saf Health Care 2003; 12:348-352
36. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40:373-383
37. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-2963
38. Bernard GR, Artigas A, Brigham KL, et al: Report of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med 1994; 20:225-232
39. Guidet B, Aegerter P, Gauzit R, et al; CUB-Réa Study Group: Incidence and impact of organ dysfunctions associated with sepsis. Chest 2005; 127:942-951
40. Lohr KN: Emerging methods in comparative effectiveness and safety: Symposium overview and summary. Med Care 2007; 45:S5-S8
41. Fernández J, Navasa M, Gómez J, et al: Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140-148
42. Arabi YM, Dara SI, Memish Z, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group: Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. Hepatology 2012; 56:2305-2315
43. Moreau R, Jalan R, Gines P, et al; CANONIC Study Investigators of the EASL-CLIF Consortium: Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144:1426-1437, 1437.e1-1437.e9
44. Kress JP, Rubin A, Pohlman AS, et al: Outcomes of critically ill patients denied consideration for liver transplantation. Am J Respir Crit Care Med 2000; 162:418-423
45. Suffredini AF, Munford RS: Novel therapies for septic shock over the past 4 decades. JAMA 2011; 306:194-199
46. Barnett JA, Sanford JP: Bacterial shock. JAMA 1969; 209:1514-1517
47. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
48. Annane D, Sébille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
49. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124
50. Annane D, Cariou A, Maxime V, et al: Corticosteroid treatment and intensive insulin therapy for septic shock in adults: A randomized controlled trial. JAMA 2010; 303:341-348
51. Barochia AV, Cui X, Vitberg D, et al: Bundled care for septic shock: An analysis of clinical trials. Crit Care Med 2010; 38:668-678
52. Rinaldi L, Ferrari E, Marietta M, et al: Effectiveness of sepsis bundle application in cirrhotic patients with septic shock: A single-center experience. J Crit Care 2013; 28:152-157